{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T14:49:09Z","timestamp":1789224549990,"version":"build-2803163510"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"China Population Welfare Foundation","award":["SLB-2-20240319-180"],"award-info":[{"award-number":["SLB-2-20240319-180"]}]},{"name":"Health Development Promotion Project-Spark Program, Scientific Research Project","award":["XHJH-0024"],"award-info":[{"award-number":["XHJH-0024"]}]},{"name":"\u2018Six talent peaks\u2019 high- level talents level B","award":["WSN-015"],"award-info":[{"award-number":["WSN-015"]}]},{"name":"Jiangsu Province 333 Senior Talent training Program"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Objects<\/jats:title>\n                    <jats:p>Tepotinib is widely utilized for treating non-small cell lung cancer (NSCLC) patients with MET exon 14 (METex14) skipping mutations. The purpose of this study is to evaluate the safety characteristics of Tepotinib in the actual environment by analyzing data from the Food and Drug Administration Adverse Event Reporting System (FAERS) database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study analyzed adverse event (AE) reports related to Tepotinib from FAERS database spanning Q1 2021 to Q4 2024. Four disproportionality analysis methods were employed: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Multi-Item Gamma Poisson Shrinker (MGPS), and Bayesian Confidence Propagation Neural Network (BCPNN). A descriptive analysis and a subgroup analysis of the time to onset (TTO) of AEs was conducted, and the Weibull distribution was used to predict temporal variations in AEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>A total of 521 AE reports involving 1,385 AEs were included in this study. Of these, 69.50% were from the elderly population. The analysis confirmed several known AEs such as death, peripheral edema, diarrhea, and blood creatinine increased while also identifying previously unreported signals, including deafness and taste disorder. For females, special attention ought to be directed toward alopecia, deafness and abdominal pain upper. For males, the onset of interstitial lung disease, pruritus and constipation requires observation. The median time to onset (TTO) of AEs was 39 days, with 43.88% of AEs occurring in the first month of treatment initiation. Additionally, the individuals aged 75 years and over the experience AEs relatively early.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study conducted a comprehensive evaluation of the real-world safety of Tepotinib. The study validates clinical assertions about Tepotinib\u2019s safety profile and identifies its novel signals, and also emphasized early monitoring of treatment. Our findings will better guide the clinical practice of Tepotinib and provide a basis for larger prospective studies in the future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0339005","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T18:40:11Z","timestamp":1766083211000},"page":"e0339005","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world safety of Tepotinib: Insights from the Food and Drug Administration Adverse Event Reporting System"],"prefix":"10.1371","volume":"20","author":[{"given":"Su","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8381-8515","authenticated-orcid":true,"given":"Xu","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"issue":"3","key":"pone.0339005.ref001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"F Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"pone.0339005.ref002","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1158\/1055-9965.EPI-19-0221","article-title":"Cancer progress and priorities: lung cancer","volume":"28","author":"MB Schabath","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"pone.0339005.ref003","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41392-025-02243-6","article-title":"Advances in molecular pathology and therapy of non-small cell lung cancer","volume":"10","author":"Q Huang","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"pone.0339005.ref004","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/2159-8290.CD-19-1446","article-title":"Targeting MET dysregulation in cancer","volume":"10","author":"G Recondo","year":"2020","journal-title":"Cancer Discov"},{"issue":"4","key":"pone.0339005.ref005","doi-asserted-by":"crossref","first-page":"940","DOI":"10.21037\/tlcr-24-98","article-title":"MET targeted therapy in non-small cell lung cancer patients with MET exon 14-skipping mutations","volume":"13","author":"JT J\u00f8rgensen","year":"2024","journal-title":"Transl Lung Cancer Res"},{"key":"pone.0339005.ref006","article-title":"From knowledge to action: the journey toward targeting the MET pathway via MET exon 14 skipping","author":"W Bogdanska","year":"2025","journal-title":"Cancer"},{"issue":"2","key":"pone.0339005.ref007","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1158\/1078-0432.CCR-21-1566","article-title":"FDA approval summary: capmatinib and tepotinib for the treatment of metastatic NSCLC harboring MET exon 14 skipping mutations or alterations","volume":"28","author":"LN Mathieu","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"7","key":"pone.0339005.ref008","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1158\/1535-7163.MCT-22-0537","article-title":"The preclinical pharmacology of tepotinib-a highly selective MET inhibitor with activity in tumors harboring MET alterations","volume":"22","author":"J Albers","year":"2023","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"pone.0339005.ref009","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jamaoncol.2023.1962","article-title":"Tepotinib treatment in patients with MET exon 14-skipping non-small cell lung cancer: long-term follow-up of the VISION phase 2 nonrandomized clinical trial","volume":"9","author":"J Mazieres","year":"2023","journal-title":"JAMA Oncol"},{"issue":"9","key":"pone.0339005.ref010","doi-asserted-by":"crossref","first-page":"103668","DOI":"10.1016\/j.esmoop.2024.103668","article-title":"A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17)","volume":"9","author":"EJ Kang","year":"2024","journal-title":"ESMO Open"},{"key":"pone.0339005.ref011","doi-asserted-by":"crossref","first-page":"1524159","DOI":"10.3389\/fphar.2025.1524159","article-title":"Real-world pharmacovigilance investigation of imipenem\/cilastatin: signal detection using the FDA Adverse Event Reporting System (FAERS) database","volume":"16","author":"P Jia","year":"2025","journal-title":"Front Pharmacol"},{"issue":"8","key":"pone.0339005.ref012","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"KJ Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"pone.0339005.ref013","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"SJ Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"pone.0339005.ref014","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1517\/14740338.2016.1167184","article-title":"Data mining spontaneous adverse drug event reports for safety signals in Singapore - a comparison of three different disproportionality measures","volume":"15","author":"PS Ang","year":"2016","journal-title":"Expert Opin Drug Saf"},{"issue":"7","key":"pone.0339005.ref015","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1210\/jc.2009-2546","article-title":"Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children","volume":"95","author":"SA Rivkees","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"pone.0339005.ref016","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1186\/s12885-024-13163-z","article-title":"MET amplification correlates with poor prognosis and immunotherapy response as a subtype of melanoma: a multicenter retrospective study","volume":"24","author":"X Cai","year":"2024","journal-title":"BMC Cancer"},{"issue":"10","key":"pone.0339005.ref017","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1038\/s41416-024-02615-9","article-title":"Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION","volume":"130","author":"T Kato","year":"2024","journal-title":"Br J Cancer"},{"issue":"10","key":"pone.0339005.ref018","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.18632\/oncotarget.2003","article-title":"HGF\/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development","volume":"5","author":"SP Hack","year":"2014","journal-title":"Oncotarget"},{"issue":"2","key":"pone.0339005.ref019","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jpainsymman.2018.11.005","article-title":"Edema of advanced cancer: prevalence, etiology, and conservative management-a single hospice cross-sectional study","volume":"57","author":"T Gradalski","year":"2019","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"pone.0339005.ref020","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/cas.16107","article-title":"Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study","volume":"115","author":"M Morise","year":"2024","journal-title":"Cancer Sci"},{"issue":"1","key":"pone.0339005.ref021","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jtho.2023.09.1444","article-title":"Brief report: tyrosine kinase inhibitors for lung cancers that inhibit MATE-1 can lead to \u201cfalse\u201d decreases in renal function","volume":"19","author":"MF Chen","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"4","key":"pone.0339005.ref022","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1093\/ckj\/sfac180","article-title":"Pseudo-acute kidney injury secondary to tepotinib","volume":"16","author":"V Wijtvliet","year":"2022","journal-title":"Clin Kidney J"},{"issue":"13","key":"pone.0339005.ref023","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.2169\/internalmedicine.4488-24","article-title":"Kidney injury in patient with non-small-cell lung cancer receiving tepotinib","volume":"64","author":"N Oda","year":"2025","journal-title":"Intern Med"},{"issue":"4","key":"pone.0339005.ref024","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/ckj\/sfad011","article-title":"Pseudo-AKI associated with targeted anti-cancer agents-the truth is in the eye of the filtration marker","volume":"16","author":"T Vanhoutte","year":"2023","journal-title":"Clin Kidney J"},{"key":"pone.0339005.ref025","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2147\/CLEP.S528454","article-title":"Exploring ototoxicity associated with capmatinib: insights from a real-world data analysis of the FDA Adverse Event Reporting System (FAERS) database","volume":"17","author":"Y Lin","year":"2025","journal-title":"Clin Epidemiol"},{"key":"pone.0339005.ref026","doi-asserted-by":"crossref","first-page":"108682","DOI":"10.1016\/j.heares.2022.108682","article-title":"The role of the stria vascularis in neglected otologic disease","volume":"428","author":"JD Johns","year":"2023","journal-title":"Hear Res"},{"issue":"31","key":"pone.0339005.ref027","doi-asserted-by":"crossref","first-page":"8200","DOI":"10.1523\/JNEUROSCI.4410-15.2016","article-title":"Hepatocyte growth factor-c-MET signaling mediates the development of nonsensory structures of the mammalian cochlea and hearing","volume":"36","author":"S Shibata","year":"2016","journal-title":"J Neurosci"},{"issue":"15","key":"pone.0339005.ref028","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1523\/JNEUROSCI.2278-19.2020","article-title":"Noncoding microdeletion in mouse Hgf disrupts neural crest migration into the stria vascularis, reduces the endocochlear potential, and suggests the neuropathology for human nonsyndromic deafness DFNB39","volume":"40","author":"RJ Morell","year":"2020","journal-title":"J Neurosci"},{"key":"pone.0339005.ref029","doi-asserted-by":"crossref","first-page":"108786","DOI":"10.1016\/j.heares.2023.108786","article-title":"Hepatocyte growth factor mimetic confers protection from aminoglycoside-induced hair cell death in vitro","volume":"434","author":"PM Uribe","year":"2023","journal-title":"Hear Res"},{"issue":"5","key":"pone.0339005.ref030","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jamaoto.2024.0184","article-title":"Hearing loss and associated 7-year cognitive outcomes among hispanic and latino adults","volume":"150","author":"AM Stickel","year":"2024","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"5","key":"pone.0339005.ref031","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1177\/0194599820910377","article-title":"Hearing loss, loneliness, and social isolation: a systematic review","volume":"162","author":"A Shukla","year":"2020","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"3","key":"pone.0339005.ref032","doi-asserted-by":"crossref","DOI":"10.1093\/geront\/gnz009","article-title":"Hearing loss and depression in older adults: a systematic review and meta-analysis","volume":"60","author":"BJ Lawrence","year":"2020","journal-title":"Gerontologist"},{"key":"pone.0339005.ref033","doi-asserted-by":"crossref","first-page":"774081","DOI":"10.3389\/fonc.2021.774081","article-title":"Managing severe dysgeusia and dysosmia in lung cancer patients: a systematic scoping review","volume":"11","author":"AS Spencer","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"pone.0339005.ref034","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.3390\/ijms24032538","article-title":"Taste and smell disorders in cancer treatment: results from an integrative rapid systematic review","volume":"24","author":"T Buttiron Webber","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"21","key":"pone.0339005.ref035","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1242\/dev.120394","article-title":"Progress and renewal in gustation: new insights into taste bud development","volume":"142","author":"LA Barlow","year":"2015","journal-title":"Development"},{"issue":"9","key":"pone.0339005.ref036","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185473","article-title":"Cellular mechanisms of cyclophosphamide-induced taste loss in mice","volume":"12","author":"N Mukherjee","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"pone.0339005.ref037","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1601-0825.2010.01719.x","article-title":"Taste dysfunction: a practical guide for oral medicine","volume":"17","author":"BJ Cowart","year":"2011","journal-title":"Oral Dis"},{"key":"pone.0339005.ref038","doi-asserted-by":"crossref","first-page":"102735","DOI":"10.1016\/j.ejon.2024.102735","article-title":"Prevalence and risk factors of chemotherapy-induced taste alterations among cancer patients: a systematic review and meta-analysis","volume":"74","author":"B Zhang","year":"2025","journal-title":"Eur J Oncol Nurs"},{"issue":"2","key":"pone.0339005.ref039","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/cam4.350","article-title":"Vismodegib, an antagonist of hedgehog signaling, directly alters taste molecular signaling in taste buds","volume":"4","author":"H Yang","year":"2015","journal-title":"Cancer Med"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0339005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T18:40:19Z","timestamp":1766083219000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0339005"}},"subtitle":[],"editor":[{"given":"Claudio J.","family":"Salomon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":39,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0339005","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]}}}